(2S,3R,4S,5R,6R)-4-[(2S,3S,4S,5S,6S)-5-[(2R,3S,4S,5S,6S)-3,4-Dihydroxy-6-methyl-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Term ID

CHEBI:149341

Synonyms

beta-D-galacto-hexopyranosyl-(1->4)-6-deoxy-beta-L-galacto-hexopyranosyl-(1->4)-6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)-alpha-D-gluco-hexopyranose
Gal(b1-4)Fuc(b1-4)Fuc(a1-3)a-Glc

Definition

References

glygen:G33304JP
glytoucan:G33304JP

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5R,6R)-4-[(2S,3S,4S,5S,6S)-5-[(2R,3S,4S,5S,6S)-3,4-Dihydroxy-6-methyl-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype where environments contain (2S,3R,4S,5R,6R)-4-[(2S,3S,4S,5S,6S)-5-[(2R,3S,4S,5S,6S)-3,4-Dihydroxy-6-methyl-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype modified by environments containing (2S,3R,4S,5R,6R)-4-[(2S,3S,4S,5S,6S)-5-[(2R,3S,4S,5S,6S)-3,4-Dihydroxy-6-methyl-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype affecting (2S,3R,4S,5R,6R)-4-[(2S,3S,4S,5S,6S)-5-[(2R,3S,4S,5S,6S)-3,4-Dihydroxy-6-methyl-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Human Disease Model